{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_16052", "batch_size": 260, "batch_pos": 64, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The language used is neutral and factual, lacking high-potency verbs or potent metaphors.", "method": "llm_batch", "batch_id": "batch_2_12704", "batch_size": 260, "batch_pos": 30, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The verb 'offers' is neutral, not a moderate verb paired with scale/impact.", "method": "llm_batch", "batch_id": "batch_3_2116", "batch_size": 260, "batch_pos": 235, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_13276", "batch_size": 260, "batch_pos": 221, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "No explicit calming cue found.", "method": "llm_batch", "batch_id": "batch_5_13088", "batch_size": 260, "batch_pos": 218, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser word combined with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_17444", "batch_size": 260, "batch_pos": 183, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "No bare negation found.", "method": "llm_batch", "batch_id": "batch_7_13652", "batch_size": 260, "batch_pos": 175, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "The segment describes advantages of mRNA vaccine technology ('offers advantages in efficacy, speed of development and production, scalability, and reliability').", "method": "llm_batch", "batch_id": "batch_8_16492", "batch_size": 260, "batch_pos": 16, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
